Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat Model

Diabetic retinopathy (DR) remains a major cause of vision loss, due to macular edema, retinal ischemia and death of retinal neurons. We previously demonstrated that acute administration of glibenclamide into the vitreous, or given orally at a non-hypoglycemic dose, protected the structure and the fu...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Marianne Berdugo, Kimberley Delaunay, Cécile Lebon, Marie-Christine Naud, Lolita Radet, Léa Zennaro, Emilie Picard, Alejandra Daruich, Jacques Beltrand, Elsa Kermorvant-Duchemin, Michel Polak, Patricia Crisanti, Francine F. Behar-Cohen
Format:	Artigo
Sprog:	Inglês
Udgivet:	MDPI AG 2021-07-01
Serier:	Pharmaceutics
Fag:	diabetic retinopathy retinal neuroprotection glibenclamide glyburide sulfonylureas diabetes complications
Online adgang:	https://www.mdpi.com/1999-4923/13/7/1095
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!